Published in:
Open Access
01-12-2022 | Prostate Cancer | Letter to the Editor
Prostate cancer multiparametric magnetic resonance imaging visibility is a tumor-intrinsic phenomena
Authors:
Amanda Khoo, Lydia Y. Liu, Taylor Y. Sadun, Amirali Salmasi, Aydin Pooli, Ely Felker, Kathleen E. Houlahan, Vladimir Ignatchenko, Steven S. Raman, Anthony E. Sisk Jr., Robert E. Reiter, Paul C. Boutros, Thomas Kislinger
Published in:
Journal of Hematology & Oncology
|
Issue 1/2022
Login to get access
Abstract
Multiparametric magnetic resonance imaging (mpMRI) is an emerging standard for diagnosing and prognosing prostate cancer, but ~ 20% of clinically significant tumors are invisible to mpMRI, as defined by the Prostate Imaging Reporting and Data System version 2 (PI-RADSv2) score of one or two. To understand the biological underpinnings of tumor visibility on mpMRI, we examined the proteomes of forty clinically significant tumors (i.e., International Society of Urological Pathology (ISUP) Grade Group 2)—twenty mpMRI-visible and twenty mpMRI-invisible, with matched histologically normal prostate. Normal prostate tissue was indistinguishable between patients with visible and invisible tumors, and invisible tumors closely resembled the normal prostate. These data indicate that mpMRI-visibility arises when tumor evolution leads to large-magnitude proteomic divergences from histologically normal prostate.